Yoshida M, Hamakubo T, Inagami T
Department of Biochemistry and Specialized Center of Research in Hypertension, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
Am J Physiol. 1994 Mar;266(3 Pt 2):R802-8. doi: 10.1152/ajpregu.1994.266.3.R802.
In an attempt to determine the mechanism of pressor action of centrally administered rat joining peptide (rJP), a pro-opiomelanocortin (POMC)-derived peptide, we investigated its action on the angiotensin and adrenergic system in the brain stem. In conscious spontaneously hypertensive rats with chronic cannulas in the cisterna magna and abdominal aorta, the pressor effect of synthetic rJP in the cisterna magna was markedly inhibited by pretreatment with losartan, an antagonist of angiotensin (ANG) II receptor specific for its AT1 subtype, and also by the nonspecific antagonist [Sar1,Ile8]ANG II but not by AT2-specific PD-123319. Pretreatment with captopril did not alter the pressor response. Adrenergic receptor antagonists, yohimbine and propranolol, did not change the pressor response. The intracisternal joining peptide administration (10 and 30 nmol) increased the concentration of immunoreactive ANG II in cerebrospinal fluid 2.4- and 5.7-fold, respectively. These results indicate that the pressor response to rJP is mediated by the release of central ANG II and AT1 receptor. This study details a biological response to rJP, the only POMC-derived peptide whose action has not been identified previously.
为了确定中枢给予的大鼠连接肽(rJP)(一种源自阿片-促黑素原皮质素(POMC)的肽)的升压作用机制,我们研究了其对脑干中血管紧张素和肾上腺素能系统的作用。在延髓池和腹主动脉植入慢性套管的清醒自发性高血压大鼠中,用氯沙坦(一种特异性作用于血管紧张素(ANG)II受体AT1亚型的拮抗剂)预处理,以及用非特异性拮抗剂[Sar1,Ile8]ANG II预处理,均可显著抑制合成rJP在延髓池产生的升压作用,但AT2特异性拮抗剂PD-123319则无此作用。用卡托普利预处理不会改变升压反应。肾上腺素能受体拮抗剂育亨宾和普萘洛尔也不会改变升压反应。向延髓池注射连接肽(10和30 nmol)可使脑脊液中免疫反应性ANG II的浓度分别增加2.4倍和5.7倍。这些结果表明,对rJP的升压反应是由中枢ANG II和AT1受体的释放介导的。本研究详细阐述了对rJP的生物学反应,rJP是唯一一种此前尚未明确其作用的源自POMC的肽。